Showing 2271-2280 of 9076 results for "".
CSF 2022 Highlights
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/csf-2022-highlights/20162/Joel Schlessinger, MD says the 2022 Cosmetic Surgery Forum was a success. The unique format of the meeting encourages presenters and audience members to interact and engage in lively discussions that allow attendees to leave the meeting with ideas they can use in their practices immediately.Lasers and EBDs: Considerations for Ethnic Skin
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/lasers-and-ebds-considerations-for-ethnic-skin/20145/Monica Li, MD reviews evidence-based practices for using lasers, energy-based devices and minimally invasive procedures to manage benign dermatoses to treat patients with skin of color. She discusses the importance of engaging patients in appropriate pre- and post-treatment care to reduce potentialThe Skin Science Podcast: Episode 1 - "The Skin Microbiome" with Doris Day, MD, FAAD, MA
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-skin-science-podcast-episode-1-the-skin-microbiome-with-doris-day-md-faad-ma/20067/Hosted by Thomas Hitchcock, Ph.D., Chief Science Officer at Crown Laboratories, The Skin Science Podcast is a monthly podcast that covers topics relating to skin health. The series will dig into hot topics within dermatology and aesthetics and will challenge the audience to think a bit differently aNew Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tLive in Las Vegas: Get Ready for DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/live-in-las-vegas-get-ready-for-derm2021/19968/The DERM2021 NP/PA CME Conference offers dermatology physician assistants and nurse practitioners an opportunity to stay up to date on the latest products, drugs, and treatments in dermatology to improve care for patients. Joe Gorelick, MSN, FNP-BC, DEF President, says this year’s conference is goinRepresentation in Marketing and Outreach
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/representation-in-marketing-and-outreach/19916/There is an apparent low rate of participation in aesthetic procedures among patients of color. Does this reflect a lack of interest or does limited representation in marketing and educational materials leave patients feeling that aesthetic interventions aren't meant for them? Panelists discuss theDERM2020 Content Recap: Brad Glick, DO, MPH
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-brad-glick-do/19840/DERM2020 Faculty Brad Glick, DO, MPH shares his thoughts on DERM2020 and some of the presentations around COVID.COVID-19 Impact: Interrupted EBD Regimens
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/covid-19-impact-on-interrupted-ebd-regimens/19764/Aesthetic treatments aren't considered essential at this time, but what do you do about patients who were in the middle of a series of energy-based treatments? Eric Bernstein, MD says the good news is that the skin doesn't forget. Now is a great time to focus on topical therapies that complement in-Valeant's Plan for Derm; VCS Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-valeant-s-plan-for-derm-vcs-highlights/18587/Amid reports that its Obagi and Solta units may be sold off, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Vegas Cosmetic Surgery has wrapped up its 12th program, gathering dermatologists, plastic surgeons, facial pFDA Warns on Expression; Lilly's Ixekizumab Data Promising
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-warns-on-expression-lilly-s-ixekizumab-data-promising/19093/Lilly's Ixekizumab phase III data look good for psoriasis, and the FDA warns on improper use of Expression hyaluronic acid as a dermal filler. Plus, Sitavig is available for herpes labialis, and Syneron's laser gets an onychomycosis clearance.